- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.11. | Teva and Immunai partner to improve clinical decision making | ||
| 14.11. | Osivax begins phase 2a booster trial for influenza vaccine | ||
| 14.11. | AC immune announces positive trial results for early Parkinson's treatment | ||
| 13.11. | Microbiotica begins human trials for ulcerative colitis treatment | ||
| 13.11. | Vivolta and Neurochase to produce brain therapy catheters | ||
| 12.11. | Lupin to develop near-zero global warming inhalers | ||
| 12.11. | Infinitopes to showcase cancer vaccine breakthroughs at SITC | ||
| 11.11. | SMC recommends Yselty for treating uterine fibroids | ||
| 11.11. | Scottish medicines consortium approves CAR T-cell therapy for blood cancer | ||
| 07.11. | New study to assess mpox vaccine in pregnant women and infants | ||
| 07.11. | Elsevier backs Pistoia Alliance for AI in drug discovery | ||
| 06.11. | Arcellx to present positive data on multiple myeloma treatments | ||
| 06.11. | MHRA grants approval for bladder cancer drug erdafitinib | ||
| 31.10. | NICE recommends remote monitoring technology for heart failure patients | ||
| 31.10. | UK dementia clinical trial participation set to boost by 'tens of thousands' | ||
| 30.10. | WHO report highlights resurgence of tuberculosis | ||
| 24.10. | NICE recommendation for new Alexion PNH treatment | ||
| 23.10. | Darzalex subcutaneous regimen approved by European Commission | ||
| 23.10. | Calluna Pharma completes successful phase 1 trial of new fibrotic disease drug | ||
| 22.10. | Valneva Scotland announces year-long support for local cancer charity Team Jak | ||
| 21.10. | NICE recommends Santen's Roclanda to treat glaucoma and ocular hypertension | ||
| 21.10. | Learna and University of Wolverhampton launch flexible healthcare courses | ||
| 17.10. | New £4.5m initiative to address UK medicines manufacturing skills shortage | ||
| 17.10. | Vivan renews five-year lease at UK biotech hub White City Place | ||
| 16.10. | HBC Immunology shares promising results for prostate cancer co-therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
